A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1759-1766

  Singh, Rishi P ^a   Srivastava, Sunil K ^a   Ehlers, Justis P ^a   Silva, Fabiana Q ^a   Bedi, Rumneek ^a   Schachat, Andrew P ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Ranibizumab; Vascular endothelial growth factors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXUDATIVE AGE RELATED MACULAR DEGENERATION; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL ANATOMY; HUMAN; LASER COAGULATION; LENS IMPLANT; OPTICAL COHERENCE TOMOGRAPHY; PHACOEMULSIFICATION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA EDEMA; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; VISION; VISUAL ACUITY; VISUAL ACUITY CHART;

EID: 84942245779     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S87043     Document Type: Article

References (21)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
2. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
3. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthal- mology. 2013;120:1046-1056.
4. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
5. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-185.
6. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neo- vascularization. Invest Ophthalmol Vis Sci. 2003;44:3186-3193.
7. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011;1.1:e5.
8. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
9. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age- Related Macular Degeneration Treatment Trials (CATT) Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119: 1388-1398.
10. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multi-center cohort study (SEVEN-UP). Ophthalmology. 2013;120:1-8.
11. Silva R, Axer-Siegel R, Eldem B, et al; SECURE Study Group. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120:130-139.
12. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175-1183.
13. Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK, A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol. 2014;98(suppl 1):i22-i27.
14. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2011. Available from: http://www.regeneron.com/Eylea/eylea-fpi.pdf
15. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
16. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Oph- thalmol. 2013;0:1-4.
17. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age- related macular degeneration. Am J Ophthalmol. 2013;156:15-22.
18. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156:23-28.
19. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:29-35.
20. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667-668.
21. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548.